Form 4: Eton Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
David Krempa, Chief Business Officer of Eton Pharmaceuticals, Inc., sold 4,166 shares of common stock on October 6, 2026 for $55.07 per share.
Summary
- Option exercise/conversion: acquired 10,522 Common Stock on October 2, 2026; holds 47,547 after (Direct).
- Open-market sale: disposed of 4,166 Common Stock at $55.07 ($229,406) on October 6, 2026; holds 43,381 after (Direct).
- Option exercise/conversion: disposed of 10,522 Restricted Stock Units on October 2, 2026; holds 21,044 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $229,406 of stock on the open market.
Insider Transactions
David Krempa — Officer (Chief Business Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-02 | Option exercise/conversion | Common Stock | 10,522 | — | — | 47,547 |
| 2026-10-06 | Open-market sale | Common Stock | 4,166 | $55 | $229.4K | 43,381 |
| 2026-10-02 | Option exercise/conversion | Restricted Stock Units | 10,522 | — | — | 21,044 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-02 | Option exercise/conversion (10,522 shares) |
| 2026-10-06 | Open-market sale (4,166 shares) |
| 2026-10-02 | Option exercise/conversion (10,522 shares) |
Keywords
insider transaction, Form 4, ETON, Eton Pharmaceuticals, Inc., bearish, David Krempa
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.